Premium
Novel pathways involved in cisplatin resistance identified by a proteomics approach in non‐small‐cell lung cancer cells
Author(s) -
Milone Maria Rita,
Lombardi Rita,
Roca Maria Serena,
Bruzzese Francesca,
Addi Laura,
Pucci Biagio,
Budillon Alfredo
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.27585
Subject(s) - vimentin , lung cancer , cisplatin , proteomics , a549 cell , downregulation and upregulation , epithelial–mesenchymal transition , carcinogenesis , cancer research , carboplatin , cell , biology , cancer , oncology , medicine , chemotherapy , immunology , gene , biochemistry , immunohistochemistry
Although platinum‐based chemotherapy remains the standard‐of‐care for most patients with advanced non‐small‐cell lung cancer (NSCLC), acquired resistance occurs frequently predicting poor prognosis. To examine the mechanisms underlying platinum resistance, we have generated and characterized by proteomic approach the resistant A549 CDDP‐resistant (CPr‐A549) and their parental A549 cells, identifying 15 proteins differentially expressed (13 upregulated and 2 downregulated in CPr‐A549). In details, we highlighted a coherent network of proteins clustering together and involved in altered protein folding and endoplasmic reticulum stress, correlated with epithelial to mesenchymal transition process and cancer stem cell markers, where vimentin played a hierarchical role, ultimately resulting in increased aggressive features. By using publicly available databases we showed that the modulated proteins could contribute to NSCLC carcinogenesis and correlate with NSCLC patients prognosis and survival probability, suggesting that they can be used as novel potential prognostic/predictive biomarkers or therapeutic targets to overcome platinum‐resistance.